Company Profile
Biodexa Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- BDRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom and listed in the U
Stock performance
1.47 USD (-7.55%)
Close
Last updated: August 6, 2026
2.61M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, BDRX closed down 7.55% at $1.47. No new same-company headline was identified in the current news window.
Company overview
Business overview
Biodexa Pharmaceuticals is a specialty pharmaceutical company focused on oncology and rare disease. Its story is built around using focused development programs to address high-unmet-need conditions.
Geographic Base and Sector Classification
Biodexa is headquartered in the United Kingdom and listed in the U.S. market. It sits in specialty pharma and oncology development.
Business Model Characteristics
The company depends on clinical progress, capital efficiency, and the ability to maintain a narrow pipeline. Investors usually watch data updates and strategic changes.
Position Within the Biotechnology Landscape
Biodexa occupies a small oncology/rare-disease niche within biotech-adjacent pharma. It is a catalyst-driven story where a limited number of programs dominate the valuation.
Future catalysts
Biodexa’s catalysts are its oncology and rare-disease programs, plus any strategic update that clarifies the company’s next move. The stock remains highly dependent on clinical proof.
Recent news
- 01
Result of General Meeting
Source: Biodexa Pharmaceuticals
- 02
Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
Source: Biodexa Pharmaceuticals
- 03
- 04
Result of Annual General Meeting
Source: Biodexa Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Biodexa Pharmaceuticals (BDRX)?
Biodexa Pharmaceuticals (BDRX) most recently closed at 1.47 USD, a -7.55% move versus the previous session.
What is the market cap of Biodexa Pharmaceuticals (BDRX)?
Biodexa Pharmaceuticals currently has a market capitalization of 2.61M USD on BioPharmSignal.
What does Biodexa Pharmaceuticals do?
Biodexa Pharmaceuticals is a specialty pharmaceutical company focused on oncology and rare disease. Its story is built around using focused development programs to address high-unmet-need conditions.
On which exchange is BDRX stock listed?
Biodexa Pharmaceuticals (BDRX) is associated with NASDAQ, United Kingdom and listed in the U, Biopharma.
What is Biodexa?
Biodexa’s catalysts are its oncology and rare-disease programs, plus any strategic update that clarifies the company’s next move.
Which conditions is Biodexa Pharmaceuticals targeting with Biodexa?
Biodexa Pharmaceuticals is associated with oncology, rare disease based on its company overview and current catalyst commentary.
How does Biodexa Pharmaceuticals describe recent progress with Biodexa?
Biodexa’s catalysts are its oncology and rare-disease programs, plus any strategic update that clarifies the company’s next move.
What is Pharmaceuticals?
Biodexa Pharmaceuticals is a specialty pharmaceutical company focused on oncology and rare disease.